Ramaprasad Srinivasan, M.D.
National Cancer Institute (NCI)
6
6
3
N/A
0
13
Research Impact
N/A
Research impact score
0
Total publications
0
Published trial results
0
Total citations
Drug Portfolio
+3 more interventions
Analytics
Trial Phases
Trial Status
Role Distribution
Activity Timeline
Clinical Trials (6)
Research Network
Collaboration Network
Research Areas & Affiliations
Therapeutic Areas
Affiliations
Similar Key Opinion Leaders
Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.
Steven A Rosenberg, M.D.
National Cancer Institute (NCI)
Shared therapeutic areas:
Worked with same sponsors:
David Avigan, MD
Beth Israel Deaconess Medical Center
Shared therapeutic areas:
Worked with same sponsors:
Murad Alam, MD
Northwestern University
Shared therapeutic areas:
Jamie Ostroff, PhD
Memorial Sloan Kettering Cancer Center
Shared therapeutic areas:
Worked with same sponsors:
howard Safran, MD
Brown University
Shared therapeutic areas:
Worked with same sponsors:
Rahul Aggarwal, MD
University of California, San Francisco
Shared therapeutic areas:
Worked with same sponsors:
James L Gulley, M.D.
National Cancer Institute (NCI)
Shared therapeutic areas:
Worked with same sponsors:
Lillian Siu, MD
Princess Margaret Cancer Centre
Shared therapeutic areas:
Eric Jonasch, MD
M.D. Anderson Cancer Center
Shared therapeutic areas:
David S Schrump, M.D.
National Cancer Institute (NCI)
Shared therapeutic areas:
Worked with same sponsors:
Publications (0)
No publications found for this investigator.
Clinical Trials (6)
Showing 6 of 6 trials
Palbociclib and Sasanlimab for the Treatment of Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Papillary Renal Cell Carcinoma (pRCC)
Vandetanib in Combination With Metformin in People With HLRCC or SDH-Associated Kidney Cancer or Sporadic Papillary Renal Cell Carcinoma
Everolimus Therapy in People With Birt-Hogg-Dube Syndrome (BHD)-Associated Kidney Cancer or Sporadic Chromophobe Renal Cancer
A Phase 2 Study of the MET Kinase Inhibitor INC280 in Papillary Renal Cell Cancer
A Phase II Study of Bevacizumab and Erlotinib in Subjects With Advanced Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) or Sporadic Papillary Renal Cell Cancer
Prospective Randomized Comparative Study of Cell Transfer Therapy Using CD8+-Enriched Short-Term Cultured Anti-Tumor Autologous Lymphocytes Following a Non-Myeloablative Lymphocyte Depleting Chemotherapy Regimen Compared to High-Dose Aldesleukin in M...
All 6 trials loaded